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ABSTRACT 
Production, Purification, and Crystallization of  
Membrane Integrated Multimeric Bax 
by 
Adelbert Villoso 
Dr. Eduardo Robleto, Examination Committee Chair 
Associate Professor 
University of Nevada, Las Vegas 
Apoptosis, or programmed cell death, is a vital process intimately involved in the 
embryonic development and homeostatic maintenance of all multicellular organisms.  
The committing step to apoptosis is regulated by a key protein, Bax, and its ability to 
integrate and form a pore structure at the outer mitochondrial membrane.   
Unfortunately, the molecular details of apoptosis remain largely unclear due to the 
lack of structural data of integral membrane (IM) Bax.  Experimental limitations of 
membrane protein production have slowed the pursuit of an IM-Bax structure simply 
because standard protocols for producing recombinant IM-Bax are inefficient in 
producing adequate quantities of IM-Bax protein. This complication makes it difficult to 
study Bax in its activated oligomeric state and essentially impossible to develop a protein 
crystal for x-ray structure analysis.  
In this thesis, we have developed solutions to these substantial problems by 
utilizing the membrane affinity properties of the protein Mistic to promote the membrane 
integration and efficient protein production of Bax in an E. coli expression system.  In 
addition, we have discovered detergent conditions optimized for high protein yield and 
stability of an activated trimeric Bax.  The activated trimer complex was further 
 iv 
 
characterized by size-exclusion chromatography and multi-angle light scattering 
techniques to detail the molecular contributions of protein in the detergent-protein 
complex.  Most importantly, the effectiveness of our protocols has produced the first x-
ray diffracting crystal of an activated Bax multimer, an invaluable tool for the solution 
structure of activated Bax complex.   This hallmark in apoptosis research will further 
complete the understanding of apoptosis mechanism and ultimately lead to the 
development of a new realm of effective pharmaceuticals. 
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CHAPTER 1 
INTRODUCTION 
1.1 Purpose of Study 
Apoptosis is a strictly regulated and complex program to regulate the homeostasis 
of a developing organism and eliminate diseased cells that may potential harm the body. 
For understanding diseases of embryonic development, neurodegeneration, autoimmune 
deficiencies, and cancer; obtaining the molecular structures of proteins involved in 
apoptosis is an immense priority (Danial and Korsmeyer, 2004; Carrington et al., 2010). 
In mitochondrial outer membrane permeabilization (MOMP) mediated apoptosis, 
the formation of a pore on the mitochondrial membrane is the committing passage to cell 
death and is strictly regulated by the B-cell lymphoma 2 (BCL-2) family of proteins.  
These pores allow for cytochrome c to diffuse from the inside of the mitochondria into 
cytoplasmic space in the cell.  These events activate apoptosome signaling cascades 
which eventually lead to cell death.   
Oligomerization of Bcl-2–associated X (Bax) of the Bcl-2 family is responsible 
for the apoptosis inducing pore and its activation is the final checkpoint before the cell 
commits to cell death.   The structural details of the Bax oligomer are essential to 
understanding the mechanism of apoptosis.  Clarification of this information would in 
turn, allow the science community the ability to troubleshoot apoptosis malfunctions.   
Moreover, the realm of membrane integrated proteins is largely untouched 
(Wallin and Von Heijne, 1998; Krogh et al., 2001).  30 to 45% of human proteins are 
membrane-embedded or membrane-associated, yet membrane protein structures account 
for less than 1% of known protein structures listed in the Protein Data Bank (Berman et 
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al., 2002).  This statistic is astonishing in that at least 50% of pharmaceuticals interact 
with membrane proteins (Klabunde and Hessler, 2002). 
In pursuit of what is referred to as the “holy grail of apoptosis,” the purpose of 
this thesis is to further understand the biochemical mechanisms of Bax oligomerization 
and therefore the foundational details of mitochondrial apoptosis (Youle and Strasser, 
2008).  We hypothesize that we have developed an integral membrane conformation of 
multimeric Bax.  Through SEC-MALS, we have quantified the molecular weight of 
protein contribution to the Bax/detergent complex and conclude that the protein oligomer 
is trimeric. 
In addition, we hypothesize that oligomeric Bax is able to form diffracting protein 
crystals.  The x-ray solution of oligomeric Bax is extremely valuable for molecular clarity 
of apoptosis as well as providing blueprints for rational drug designers in cancer 
pharmaceuticals. 
This thesis develops techniques for relatively high yields of IM Bax and prompts 
the finding of an inevitable x-ray solution.  The protocol used to obtain these data 
displays the effectiveness of the fusion partner Mistic and should push science to study 
IM proteins that were previously impossible to study in vitro due to protein expression 
limitations.  With a deeper mechanistic understanding of Bax oligomerization and the 
eventual high resolution structure of IM Bax, we hope to contribute to the improvement 
of human health by developing the protein blueprints for rational drug designers. The 
wealth of knowledge from a Bax structure will initiate a new stage of production of 
highly specific and efficient pharmaceuticals to solve problems of aberrant apoptosis. 
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Although the development of a Bax protein crystal is a significantly ambitious 
task, the probability for success is greatly enhanced by our recent experiences in 
obtaining the first crystal structure of the human protein uridine phosphorylase 2 (UPP2).  
Publication details can be seen in the appendix section of this thesis. 
1.2 Significance to Development and Disease 
Within an entire lifetime, the innumerable events of cell proliferation, the growing 
biochemical inefficiencies occurring with age and the unavoidable exposure of DNA 
damaging elements, the occurrence of biochemical mistakes seem inevitable in cellular 
replication.  Surprisingly, despite the trillions of mutable cells the propagation of cancer 
can originate from, cancer on average occurs less than once in a lifetime (Lowe et al., 
2004).  Multicellular organisms in response to these highly detrimental events have 
evolved networks of aberrant tumor control, one of the most important being apoptosis.  
Cancer has taken the spotlight for focus to discern the mechanisms of apoptosis.  
Currently, popular methods of treating cancer include surgery, chemotherapy, and 
radiation therapy and although effective in eliminating cancer cells, the loose specificity 
of these treatments has long been a major drawback as they can result in collateral 
damage to healthy cells.   
It is evident that in terms of molecular biology, there is much to be learned in the 
treatment of cancer. For example, it was originally believed that a chemotherapeutic 
barrage of damage on the cellular components of a tumor defined the lethal factor in 
eliminating cancerous cells. It is now known that chemotherapeutic drugs do not directly 
kill but instead trigger the same innate tumor-suppressor networks that halt the events of 
cancer proliferation, or in other words, chemotherapy activates tumor self destruction  
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(Lowe et al., 2004). Interestingly, the decision for cells to proliferate or execute apoptosis 
is controlled by connected pathways. Chemotherapy can potentially disable proliferation 
checkpoints which undesirably uncouple apoptosis pathways, creating unresponsive 
tumors (Lowe et al., 2004).   
It is also shown that anti-apoptotic proteins are overexpressed in both solid tumors 
and hemotologic malignancies (Korsmeyer, 1999; Cory et al., 2003).  Accumulated 
genetic errors resulting in gene amplification in Bcl-2 genes is observed in almost all 
follicular lymphomas and approximately 20% of diffuse B-cell lymphomas (Yunis et al., 
1987; Yang and Korsmeyer, 1996).  Growing studies on apoptosis and the Bcl-2 family 
have also detailed other survival mechanisms of tumor proliferation.  Errors in upstream 
factors such as AKT possibly promote tumor survival by decreasing transcription of pro-
apoptotic proteins (Grad et al., 2000). Transcription factors such as STAT, Rel/NF-
[kappa]B, and Ets have been shown to modulate the expression levels of Bcl-XL and in 
turn over sequester pro-apoptotic signals  (Wendel et al., 2004). The gained ability for 
cancer to sequester pro-apoptotic signals with anti-apoptotic proteins is speculated to be a 
survival strategy for tumors, allowing for immunity to death signals and 
chemotherapeutics acting on pro-apoptosis pathways.  
The repeating pattern of high expression of pro-survival proteins in cancers has 
inevitably led to the development of ABT-737, a BH3-only mimetic capable of high 
affinity binding to anti-apoptotic proteins.  The binding of ABT-737 liberates sequestered 
pro-apoptotic proteins to induce apoptotic signals. Although effective independently, 
ABT-737 also acts as a sensitizer to increase the effects of other chemotherapeutic 
compounds such as proteosome inhibitors.  The strategy of orchestrating attacks at 
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multiple pathways is promising, enabling the elimination of cancerous cells while 
preventing them from resisting treatment (Oltersdorf et al., 2005).  
With many varying characteristics of cancer tissue types, focus on treating a 
commonality between all cancers is vital.  A faulty apoptosis program is one common 
theme of proliferating cancer, therefore the details of the mechanism of apoptosis are 
urgent for advancements in oncology. 
The Bcl-2 family possesses considerable responsibility in maintaining the immune 
system as well.  Lymphocytes must maintain criteria that act to further increase reactivity 
to foreign substances while remaining tolerant to self; this is the central principle of a 
functioning immune system (Carrington et al., 2010).  The proapotosis signals are 
activated in developing lymphocytes failing to meet standards that conserve proper 
immune system integrity. For example, if newly created B or T cells fail to undergo 
productive rearrangement of their T-cell receptor genes, they cannot receive signals 
through the antigen receptors and as a result are signaled for apoptosis.  Qualified 
immature thymocytes with productive TCR gene rearrangements must express receptors 
that bind host MHC class I or class II molecules.  Receptors that cannot bind MHC class I 
or class II will fail to respond to foreign antigens presented by host MHC molecules and 
are therefore signaled for destruction.  B cells undergo a similar checkpoint that they 
must pass in order to proceed in maturity.  Lastly, B and T cells that recognize self-
antigens are negatively selected and eliminated.  Remarkably, after the battery of 
checkpoints the B and T cells undergo, only 10% meet the strict immunological criteria 
(Marsden and Strasser, 2003).   
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Apoptosis also has a role in the halting of an immune response.  Once a pathogen 
is successfully eliminated, the Bcl-2 family is also responsible for the termination of 
active effector plasma cells and  (Sprent and Tough, 2001).  A lingering immune 
response can have deleterious damage. For example, diseases such as the lymphocytic 
choriomeningitis virus elicit a extremely  self-damaging immune system reaction 
(Gallimore et al., 1998).   
In contrast, alteration of apoptosis for the inhibition of a proper immune response 
can be beneficial for patients of organ transplantation due to the elimination of immune-
mediated rejection (Carrington et al., 2010).  Treatment of ABT-737 on immature B and 
T cell populations in mouse immune systems selectively reduced leukocyte populations, 
inhibited humoral immunity, and slowed cytotoxic T lymphocyte response. This special 
modulation of the Bcl-2 family allowed for the protection of transplanted islet allografts, 
leading to glucose processing and the essential reversal of diabetes (Carrington et al., 
2010).   
Lastly, apoptosis is crucial in all steps in embryo development.  The apoptotic 
process is seen as early as the blastocyst phase, where it shaping the inner cell mass and 
trophoectoderm by controlling cell numbers (Hardy, 1997).  Later in development, 
apoptosis is responsible for the elimination of abnormal or misplaced cells and also 
sculpts key biological structures (Jacobson, 1997).  For example, the role of apoptosis is 
seen in the development of the fingers in the hand.  Cells that develop in between each 
digit are eliminated through apoptosis (Mori, 1995). 
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1.3 Known Structural Characteristics of the Bcl-2 family and Bax 
To date, our best solution structure of Bax has been the inactivated, monomeric 
conformation obtained through NMR spectroscopy (Suzuki et al., 2000).  Four sequence 
conserved alpha helical domains, labeled "Bcl-2 homology" (BH1-4) domains, define the 
Bcl-2 family (Petros et al., 2004). The Bcl-2 family is further categorized by function:  
the pro-apoptotic multidomain, anti-apoptotic, and BH3-only proteins. The anti-apoptosis 
proteins (Bcl-2, Bcl-XL, A1/BF1, Bcl-W) show sequence conservation in three to four 
BH domains and function as to bind pro-apoptotic proteins, inactivating them (Youle and 
Strasser, 2008).  Second, pro-apoptosis proteins  Bak and Bax are divided into multiple 
BH domains containing three conserved domains (BH1-3) and function by homo-
oligomerizing at the mitochondrial membrane to form a cytochrome c releasing pore 
(Youle and Strasser, 2008). Lastly, the BH3-only proteins only show homology in the 
BH3 domain and are theorized to either release anti/pro complexes to allow pro-apoptotic 
proteins to commit to pore formation or activate pro-apoptotic proteins directly  (Youle 
and Strasser, 2008). 
A Bax monomer is composed of domains BH1-BH3 and is assembled by 9 alpha 
helices.  α4-α5 compose the BH1 domain, α7 and α8 the BH2, and α2 the BH3. The 
conformational change of the monomeric Bax marks its activation, allowing for 
translocation, and oligomerization with other Bax molecules.  Bax is structurally similar 
to anti-apoptotic protein Bcl-XL.  Both proteins form a hydrophobic groove in their BH1-
3 domains, however, unlike Bcl-XL, Bax occupies this hydrophobic groove with its own 
α9 or C-terminal tail (CT) (Muchmore et al., 1996; Suzuki et al., 2000). 
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Figure 1:  Structure of monomeric Bax solved by NMR spectroscopy (Suzuki et al., 
2000). 
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Hydrophobic α5 composes the core of Bax which is surrounded by the remaining 
eight amphipathic alpha helices.  α2 contains the BH3 domain and together with α4 and 
α5, face the hydrophobic core of the protein.  α4 and α5 are also known as the homo-
oligomerization domain, responsible for the oligomerization to other Bax molecules 
(George et al., 2007).    
Helices α6 and α9 are independently important for membrane translocation.  
Knock-out studies removing individual α6 and α9 helices do not abolish translocation, 
however removal of both helices halts ability of Bax to translocate to the mitochondrial 
membrane (George et al., 2010).  A Bax molecule contains two cysteine residues, 
Cysteine-62 at the center of α2 and Cysteine-126 at the end of α5.  Both cysteine 
residues are potentially available for disulfide bridges between other Bax molecules or 
heterodimerization with other members of the Bcl-2 family (D'Alessio et al., 2005). 
Activation of monomeric Bax induces a conformational shift in the molecule. 
This disengages the α9 from the hydrophobic groove, exposing the BH3 domain totrigger 
translocation to the mitochondrial membrane which allow oligomerization of Bax 
molecules or pro-survival proteins (Dewson and Kluck, 2009).   
The remaining helices hold the important function of maintaining the monomeric, 
inactive integrity of Bax.  Surprisingly, disruption of the helices causes conformational 
change and spontaneous activation of Bax (George et al., 2010).   
1.4 Bcl-2 Regulation and Bax Activation 
Once surpassing anti-apoptotic signals, pro-apoptotic proteins localize to the 
mitochondrial membrane forming pore structures.  The pore structures allow cytochrome  
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c to diffuse out of mitochondrial space into the cytosol.  There, it will activate 
apoptosome complexes and a subsequent caspase cascade, ultimately leading to cell death 
(Reed, 2004) 
Cellular stresses, such as DNA damage, hypoxia, and oncogene activation are the 
initial signals of apoptosis activation.  These signals activate tumor suppressor p53, 
which is a direct transcription factor of Bax, as well as BH3-only proteins Puma, Noxa, 
and Bid (Nakano and Vousden, 2001; Hemann and Lowe, 2006). 
The complex interactions of pro-apoptotic multidomain, anti-apoptotic, and BH3-
only proteins dictate cell survival or death in MOMP apoptosis (Bleicken et al., 2009).  
Pro-apoptotic multidomain proteins consist of 2 members, Bcl-2 homologous 
antagonist/killer (Bak) and Bcl-2–associated X (Bax).  Though redundant in their 
functions, inactivated Bak is a constituent of the mitochondrial membrane while, 
inactivated Bax is cytosolic and neither protein interacts with each other (Wei et al., 
2001).     
The exact mechanism of Bax activation awaits clarification though there are three 
supported theories.  The direct activation theory suggests that BH3-only proteins, such 
as truncated-Bid (t-Bid), Bim, Puma, and RACK1, act as direct pro-apoptotic signals.  
Contact with BH3-only proteins cause a conformational change in Bax to allow for a 
series of structural transitions causing homo-oligomerization and subsequent 
translocation to the mitochondrial membrane (Letai et al., 2002; Certo et al., 2006; 
Walensky et al., 2006; Wu et al., 2010).   
Since a heterodimer of a BH3-only protein interacting with Bax has never been  
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observed, a “hit-and-run” mechanism has been proposed.  This mechanism 
suggests the Bax/BH3-only interactions are transient.  For example, the “hit” may occur 
when a Bim protein attaches to the back of a Bax monomer, which displaces the C-
terminal tail of Bax (Gavathiotis et al., 2008).  Subsequently, the BH3 region of a 
separate Bax molecule may disrupt the groove allowing for the formation of a homo-
oligomer while simultaneously displacing tBid, allowing it to “run” away (Wei et al., 
2000; Gavathiotis et al., 2008). 
A second theory called the displacement model suggests that the presence of anti-
apoptotic proteins continuously sequester pro-apoptotic Bax and Bak from activation.  
Only when a BH3-only protein competes and binds anti-apoptotic proteins does the 
anti/pro-complex separate, allowing  Bax to continue with the default pore formation 
(Willis et al., 2005; Willis et al., 2007; Fletcher et al., 2008).   
A third theory called the "embedded together" model combines both direct and 
indirect activation theories and suggests that lipids and proteins in the mitochondrial 
outer membrane are the key to coordinating MOMP (Leber et al., 2007).  Evidence in this 
thesis supports the importance of the membrane in MOMP. 
In any case, the end point is the formation of a Bax-only pore that allows 
cytochrome c from intermitochondrial space to diffuse out.  Cytosolic cytochrome c 
binds Apaf-1 which leads to the assembly of the apoptosome and activation of caspase 9.  
Caspase 9 then activates caspase-3, caspase 6, and caspase 7 for  rapid cleavage of 
multiple targets leading to the packaging and phagocytosis of the apoptotic cell  (Luthi 
and Martin, 2007; Ravichandran and Lorenz, 2007). 
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Figure 2:  Bcl-2 regulation of mitochondrial outer membrane permeabilization.  
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1.5 Present Problems in IM Protein Production and a Mistic solution 
The halting bottleneck in the elucidation of recombinant IM proteins is simply 
producing adequate amounts for experimentation.  Inducible expression systems in E.coli 
of soluble proteins are extremely reliable in producing high yields.   Adversely, a reliable 
system for expressing IM proteins is lacking,  making IM protein production extremely 
difficult (Tate, 2001).  There are two theories for the IM protein production limitation. 
 One, IM protein translocation may require targeting signals that may not be recognized 
by the bacterial host, making membrane integration impossible.  Second, newly translated 
membrane proteins require chaperones in order to be directed from the ribosome to the 
cellular membrane.  As membrane protein expression increases, the host cells 
translocation machinery becomes increasingly overwhelmed with the movement of 
recombinant IM proteins.  This results in the neglect of vital host IM proteins.  The 
essential hijacking of translocon machinery leads to cell toxicity (Roosild et al., 2005). 
To solve complications of both IM protein signal recognition and translocation 
overloading, we utilized the fusion partner protein Mistic as an independent translocation 
system.  Discovered in Bacillus subtillus, Mistic is a 13 kDa protein and has an innate 
affinity to the lipid bilayer. Linking Mistic to the N-terminus of human Bax protein 
allows for the translated protein to be independently moved from the ribosome to the 
lipid bilayer which allows Bax to be in close proximity to the membrane for integration.  
 The fact that no known accessory proteins or chaperones are required for proper 
Bax folding supports the probability that Bax will integrate correctly into the membrane 
during Mistic translocation. 
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Figure 3:  A step-by-step progression of  Mistic-fused translation.  Mistic is expressed at 
the N-terminus of a target protein.  The innate affinity of Mistic to the bacterial 
membrane trails the target protein allowing for membrane integration of the protein-of-
interest. 
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1.6 Detergents 
When embedded in their native membranes, IM proteins remain properly folded 
and active. Once extracted from the membrane, the lack of the amphipathic environment 
causes protein misfolding, loss-of-function, and aggregation (Prive, 2007). Studies on IM 
proteins have facilitated the use of non-ionic detergents to act as membrane surrogates to 
maintain protein stability. Detergents are water-soluble, surface-active agents that due to 
their amphiphilic character will self-aggregate in solution to form micelles (Sigma-
Aldrich, 2004). 
The problem of determining a compatible detergent is not simple.  The numbers 
of detergents available for in vitro studies are enormous, with each detergent having its 
own complex properties.  Generally, detergents have two segments which are common to 
all detergents.  The first segment, called the hydrophilic head group, have a strong 
influence on interactions with proteins.  The second segment, called the hydrophilic alkyl 
chain, affects the detergent critical micelle concentration (CMC) and aggregation 
number.  Composition of either segment causes diverse interactions with IM proteins. 
The CMC is the minimal concentration of detergent in order for micelles to form.  
The aggregation number is a property unique to each detergent and signifies the number 
of detergent molecules in a micelle.  For general purposes, concentrations of buffers 
containing detergent should be well above the CMC in order to be an effective solubilzer 
(Prive, 2007).  During the extraction of membrane proteins, the critical solubilization 
concentration (CSC), which is the minimal detergent concentration required to disrupt 
membranes into a micellar dispersion, must also be surpassed.   
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The use of a “gentle” detergent is essential for protein crystallization.  Strong 
detergents such as sodium dodecyl sulfate (SDS) contain reactive head groups and are a 
protein denaturant.  Therefore the use of SDS is undesirable in maintaining protein 
stability and is not used when attempting to create a protein crystal.  On the other hand, 
weaker detergents such as octyl-glucoside have non-reactive head groups but due to the 
long alkyl chain, high concentrations are required in order to keep membrane proteins in 
solution which may be detrimental to protein crystallization (Prive, 2007). 
Unfortunately, the optimal detergent for membrane protein extraction or even 
maintaining protein stability is not necessarily optimal for protein crystallization.  The 
protein, detergent, and aqueous buffer comprise the three components in a membrane 
protein crystal lattice and are referred to as the protein-detergent complex (PDC).  Each 
component of the PDC has independent physical properties but together must form stable 
complexes.  For example, protein-protein contacts form the primary scaffolding of the 
lattice however, in order to form crystals, IM proteins must interact within embedded 
flexible detergent micelles.  Small micelle detergents like LDAO form small belts around 
the transmembrane region of proteins allowing for greater protein-protein interactions 
however, these detergents are often destabilizing.  In contrast, large micelle detergents 
are much gentler to proteins but the large size of the detergent prevents protein-protein 
interactions (Prive, 2007).    
Protein aggregation is usually an irreversible process that is a result of using an 
incompatible detergent.  Aggregation seems to occur with even minor denaturing effects.   
Small misfolds may lead to non-specific interactions of exposed surfaces meant to be 
buried in the protein complex.  Also, if the detergent does not fully mask the 
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transmembrane region of IM proteins, the hydrophobic regions of the IM proteins may 
associate to cover their surfaces from the aqueous buffer.  In brief, the flexible and 
dynamic nature of the detergent belt surrounding the protein makes the formation of a 
strong crystal lattice very difficult (Prive, 2007).  
The ability to shift from cytosolic to membrane-bound conformation makes Bax 
an extremely interesting IM protein. Studies speculate that a hydrophobic active site is 
shielded when Bax is in its cytosolic, inactive form.  Once activated by a BH3-only 
protein, Bax shifts to an open conformation.  This open conformation exposes its 
hydrophobic surface to interactions with other activated Bax molecules forming 
oligomers.   
 
   
Sodium dodecyl sulfate                                                              
 
Octyl gluocoside 
                            
Figure 4: Structural Comparison of Strong and Weak Detergents (ChemBook, 2008). 
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Luckily, strong evidence has also shown that Bax in non-ionic detergent micelles 
shifts conformation into an activated form.  This will allow for in vitro oligomerization 
without the need for BH3-only proteins (Antonsson et al., 2000; Le Maire et al., 2000). 
1.7 Size-Exclusion Chromatography and Multi-angle Light Scattering Analysis 
Aggregates, heterogeneous protein sample, and any minute contaminants are 
inevitable in a protein preparation yet are highly detrimental to protein crystallography. A 
series of purification methods must be taken at every step to protein crystallization trials. 
Size-exclusion chromatography (SEC), or gel filtration, is a method widely used 
in protein purification.  In brief, a heterogeneous protein sample is run through a gel 
matrix packed column. The matrix is composed of porous spherical particles that allow 
buffer and sample to diffuse through while it is traveling the column.  Larger molecules, 
having difficulty diffusing into the matrix, will elute faster while smaller molecules will 
spend more time inside the matrix before finally eluting off.  The timing at which 
molecules elute off the column is used to predict the molecular weight of cytosolic 
proteins.   
Unfortunately, the elution timing in SEC to determine molecular mass of a protein 
becomes unreliable when studying IM proteins.  In comparison to cytosolic proteins, 
detergent-protein complexes will have altered adsorption behavior to the SEC column 
due to the presence of detergent. More importantly, the presence of detergents increase 
the molecular mass of IM proteins, making proteins elute much faster, falsely indicating a 
larger protein. 
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1. Sample is applied to the column.
2.  Column is packed with porous gel filtration medium 
that separate molecules based on size.
3. Larger molecules have lower retention times due to inability to diffuse within 
the porous medium and elute first.  In contrast, small molecules spend more time 
diffusing into the pores thus requiring more time to pass through the column.
 
Figure 5:  Outline of Size-exclusion chromatography (GE Healthcare, 2002).  Timing of 
protein sample elution is predictable and based on molecular size.  Larger molecules have 
lower retention times due to inability to be “trapped” within the porous medium.  In 
contrast, small molecules spend more time diffusing into the pores thus requiring more 
time to pass through the column. 
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To obtain an accurate measurement of molecular masses of both the detergent and 
protein components, multi-angle light scattering in conjunction with SEC must be used in 
order to obtain light scattering, UV absorption, and differential refractive index 
measurements.  For simplicity, we use the commercially available Astra software 
package (Wyatt technologies) to discern the molecular mass contribution of protein and 
detergent in these complexes.  In short, by combining the change in refractive index as a 
function of protein concentration (dn/dcprotein), the change in refractive index as a function 
of detergent concentration (dn/dcdetergent), and measuring the refractive index and UV 
absorption, Astra can determine detergent concentration (δ) of a given solution.  δ is then 
used to find the refractive index increment (dn/dccomplex), the change in refractive index of 
the solution as a function of protein concentration, using the light scattering and 
refractive index measurements to determine the molecular mass of the protein/detergent 
micelle.  Again, δ is then used to determine the contributions of protein and detergent to 
the molecular mass of the complex. Ultimately, these readings are used to determine 
protein contribution to the protein-detergent complex (Wyatt-Technology, 2010). 
1.8 Protein Crystallography 
Unfortunately, the biggest drawback of NMR in the study of oligomeric 
molecules is their large sizes. Larger complexes, like a trimeric Bax (75 kDa) will have 
slower tumbling rates and shorter NMR signal relaxation times causing poor resolution of 
the protein.  Also, increased molecular weight introduces complexity due to the increased 
interactions amongst the NMR-active nuclei (Tamm and Liang, 2006).  Due to these 
paralyzing limitations, we turn to protein crystallography in attempt to solve the structure  
of oligomeric Bax.   
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Protein crystallography is a technique over 170 years old historically used to 
purify proteins from a heterogeneous mixture and to measure purity of a given protein 
preparation (McPherson, 1999).  Presently, protein crystallography with the use of x-ray 
diffraction has grown to be one of the most valuable tools in generating high resolution 
three dimensional structures.  Sadly, the production of a protein crystal is a stifling hurdle 
in structural biochemistry simply because we lack the insight to know what crystallizes a 
protein.  The dynamic nature of proteins makes it impossible to predict what parameters 
stabilize each unique protein in order for it to crystallize.  In addition, lessons learned 
from one crystallization success do not translate to even similar proteins due to the fact 
that each amino acid sequence possesses its own three dimensional structure and 
therefore surface characteristics. Scientists have even gone to great distances in attempts 
to eliminate variables such as gravity, leading to crystallography laboratories in space. 
For a crystal to form, the properties of the solution and, in the case of IM proteins, 
the detergent must allow interactions between protein molecules to form stable geometric 
arrangements.  Unlike inorganic molecules, the robustness and flexibility of proteins 
hinder its ability to organize in geometric lattices.   Moreover, many proteins are 
composed of multiple subunits or form oligomeric complexes, each partition having its 
own physical properties and sometimes connected by flexible regions.  In order to 
“stiffen” protein complexes, researchers are known to truncate flexible proteins regions.   
The practice of doing so is controversial, however, since it can be argued that all regions 
affect the protein complex and therefore no regions should be omitted.  This is especially 
true in Bax studies where truncation of the flexible α9 destroys the oligomerization 
capabilities of Bax (Ivashyna, 2009). 
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Due to the tremendous variables scientists must account for, many techniques to 
obtain a protein crystal are extremely time consuming and are determined empirically.  
During typical crystallography trials, a crystallographer endures a repeated series of 
testing conditions and observing results.   The formation of any potential “hits” may take 
weeks to months and even after, rounds of optimization trials may be just as time 
consuming.  It is very common for protein crystallographers to process tens of thousands 
conditions to obtain a protein crystal. 
 Also, the appearance of crystals do not equate to success.  There is an unfortunate 
possibility that the crystallographer has used conditions that favor the crystallization of 
salts in the solution and may only realize it when no diffraction pattern is obtained.  
Another false positive may come in the form of a protein crystal that cannot diffract x-
rays.  There are techniques to defend crystallographers from these devastating results 
such as protein crystal dyes and crystal shatters tests, though the appearance of a 
diffraction pattern when placed in an x-ray beam is the absolute confirming test that the 
sample is in fact protein. 
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Physical factors Chemical factors Biochemical factors 
Temperature Precipitant type Sample purity 
Methodology Precipitant concentration Macromolecular impurities 
Time pH and buffer Aggregation 
Pressure Ionic strength 
Posttranslational 
modifications 
Gravity, convection and 
sedimentation 
Reducing/oxidizing 
environment Sample source 
Vibration and sound Sample concentration Sample storage 
Magnetic fields Metal ions Proteolysis 
Electric fields Detergents Chemical modifications 
Dielectric properties Small molecule impurities Sequence modifications 
Viscosity Polyions Sample symmetry 
Equilibration rate Crosslinkers Sample pI 
Nucleants Heavy metals Sample history 
Volume Reagent source Ligands, co-factors, inhibitors 
Particulate/amorphous material Reagent purity Microbial contamination 
Surface of crystallization device Reagent formulation Purification methods 
Sample handling   
 
Table 1:  Major variables affecting protein crystallization (Leunissen, 2001). 
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CHAPTER 2 
METHODOLOGY 
2.1 Mistic-fused Bcl-2 family Constructs 
Previous to this thesis, no study of the effectiveness of Mistic towards Bcl-2 
protein expression had been conducted.  Since many of the Bcl-2 family members are 
speculated to integrate into the mitochondrial membrane, a library of Mistic-fused Bcl-2 
family proteins was created to test for Mistic compatibility with Bcl-2 family members 
for high yield protein expression.  The library consisted of an array of full-length Bcl-2 
family proteins cloned, using the recombination “LR reaction” of the Gateway Pro Kit 
(Invitrogen, Carlsbad, CA) to the 3’ of a Gateway adapted pMis vector.   
To form the construct library, 1 µL of entry pMis vectors were incubated with 1 
µL of one of the target Bcl-2 destination vectors and 2 µL of TE buffer, pH 8.0.  Then, 
1 µL of the provided “LR Clonase II Enzyme Mix” was added to the mix and allowed to 
incubate at 25°C.  Subsequently, 1 µL of the provided Proteinase K solution was added 
and allowed to incubate for 10 minutes at 37°C.  Transformation was executed and 
described in section 2.3 “Plasmid Transformation” using Novablue Competent Cells. 
To amplify that the recombination reaction, four individual colonies were cultured 
in 10 mL of Terrific Broth (Novagen, Gibbstown, NJ) at 37°C in a 14 mL Polystyrene 
Round-Bottom Tube (Becton Dickinson Labware, Franklin Lakes, NJ) overnight.  A 
GenElute Plasmid Miniprep Kit (Sigma-Aldrich, Saint Louis, MO) was utilized to purify 
the plasmid from each of the four cultures. 
Cells were pelted by in the 14 mL Polystyrene Round-Bottom Tube at 3000 rpm 
using a Allegra X-15R Centrifuge (Beckman Coulter, Brea, CA).  Remaining media was 
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decanted and the pellet was resuspended using 200 µL of the provided “Resuspension 
Solution”, vortexed vigoursouly and transferred into a 2.5 mL centrifuge tube.  Cells 
were lysed using the 200 µL of the provided “Lysis Solution” and the contents were 
inverted 5 times.  Cell debris was precipitated by adding 350 µL of the 
“Neutralization/Binding Solution” and the contents were inverted 5 times and centrifuged 
using the Centrifuge 5424 (Eppendorf, Hauppauge, NY) at 12,000 rpm for 10 minutes.  A 
provided “Miniprep Binding Column” was prepared by adding 500 µL of the “Column 
Preparation Solution” and centrifuging at 12,000 rpm two times in 30 second intervals 
before decanting the run-through.  The lysate was loaded into the prepared binding 
column and centrifuged at 12,000 rpm for 30 seconds.  The column was transferred to a 
new 2.5 mL centrifuge tube and 50 µL of water was added and centrifuged at 12,000 rpm 
for 1minute.  Plasmid sequences were verified by sending them to Nevada Genomics 
Center for analysis. 
The pMis vector is an IPTG inducible system, possessing a T7 promoter and an 
ampicillin resistance gene.   Expression of the Mistic-fused Bcl-2 family protein 
produced an amino acid chain consisting of an octahistidine tag, followed by Mistic, the 
linker, a thrombin cleavage site, the Bcl-2 family member target protein, and finally a 
“Strep-Tag II” (GE Healthcare, Piscataway, NJ).  The linker is a variable length amino 
acid chain meant to optimize the positioning of the target protein in relation to the 
membrane.  They are notated small (7 residues), medium (14 residues), or large (21 
residues) and can have an orientation reversing transmembrane helix.  Constructs  
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displayed differing expression behavior however, due to the success in protein expression 
and significance that Bax has in the MOMP pathway; we focused our research attempts 
on the characterization of Bax. 
A 
 
B 
MK[HHHHHHHH]1GG[LVPRGS]2HG[MKVTSEEKEQLSTAIDRMNEGLDVFIQFY
NESEIDEPLIQLEDDTADLMKQARDLYGQEKLNEKLNTIIKQILSISLSGEGEKE]3[
TSDYKDDDDK[LVPRGS]2[TSLGGSKKAGGT]7]4[MDGSGEQPRGGGPTSSEQIMK
TGALLLQGFIQDRAGRMGGEAPELALDPVPQDASTKKLSECLKRIGDELDSNME
LQRMIAAVDTDSPREVFFRVAADMFSDGNFNWGRVVALFYFASKLVLKALCTK
VPELIRTIMGWTLDFLRERLLGWIQDQGGWDGLLSYFGTPTWQTVTIFVAGVLT
ASLTIWKKMG]5N[PAFLYKVV]7DDPNSSS[WSHPQFEK]6 
Figure 6:  A.  Model of MisticBcl-2 construct.  B.  Sequence of Bax with long-linker. [1] 
Histidine-tag [2] Thrombin Cleavage Site [3] Mistic [4] Large Linker (underlined) [5] 
Bax [6] Strep-Tag II [7] Residual recombination artifact 
 
 Once the protein expression yield for the initial MisticBax with a long linker 
construct reached a plateau (~ 2.5 mgs/ per 8 liters), we opted to send our MisticBax 
sequence to DNA 2.0 (Menlo Park, CA) to be synthesized into bacterial expression 
optimized vectors in attempts to increase our protein yield.  In short, DNA 2.0 assembles 
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short single-stranded oligonucleotides to form the MisticBax sequence.  This synthesized 
sequence is subsequently cloned into a pJexpress411 vector.  Major changes in the 
synthesized plasmids in comparison to the Gateway-adapted pMis are the removal of one 
thrombin site within the Bax gene, and the replacement of the Ampicillin resistance gene 
to a Kanamycin resistance. 
MK[HHHHHHHH]1GGSGGSGSHG[MKVTSEEKEQLSTAIDRMNEGLDVFIQFYNE
SEIDEPLIQLEDDTADLMKQARDLYGQEKLNEKLNTIIKQILSISLSGEGEKE]2[TS
DYKDDDDK[LVPRGS]6[TSLGGSKKAGGT]7]3[MDGSGEQPRGGGPTSSEQIMKTG
ALLLQGFIQDRAGRMGGEAPELALDPVPQDASTKKLSECLKRIGDELDSNMELQ
RMIAAVDTDSPREVFFRVAADMFSDGNFNWGRVVALFYFASKLVLKALCTKVP
ELIRTIMGWTLDFLRERLLGWIQDQGGWDGLLSYFGTPTWQTVTIFVAGVLTAS
LTIWKKMG]4N[PAFLYKVV]7DDPNSSS[WSHPQFEK]5 
Figure 7:  Sequence of Synthesized MisticBax sequence. [1] Histidine-tag [2] Mistic [3] 
Large Linker (underlined)[4] Bax [5] Strep-Tag II [6] Thrombin cleavage[7] Residual 
recombination artifact 
2.2 Detergent Screen 
5 detergents were selected based on prior successes of other membrane protein 
studies and the detergent LAPAO was selected due to its possession of a zwitterionic 
head group and structural similarity to LDAO. 
The screening process to determine a compatible detergent was implemented at 
the 2nd Nickel Bead wash described below in section 2.5 “Protein Extraction and 
Purification” until the SEC run. The effectiveness of the detergent was determined by the 
presence of a single UV absorption peak during the SEC run. 
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n-Dodecyl-n,n-Dimethylamine-n-Oxide (LDAO)
n-Dodecyl-B-D-Maltopyranoside (DDM)
n-Decyl-B-D-Maltopyranoside (DM)
Cymal-5 
N-[3-(dimethylamino)propyl]dodecanamide N-oxide (LAPAO)
n-Undecyl-B-D-Maltopyranoside (UDM) 
Figure 8:  Detergent Structures (ChemBook, 2008) 
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2.3 Plasmid Transformation 
One µL of the MisticBcl-2 vector was incubated with two aliquots of 20 µL 
competent cells BL21 (Novagen, San Diego, CA)  ,or NovaBlue competent cells when 
verifying the sequence, each in a 2.5 mL centrifuge tube on ice for 30 minutes.  The 
incubated competent cells were heat-shocked at 42°C water bath for 30 seconds then 
placed on ice for 1 minute.  A 90 µL aliquot of the provided SOC media was added to 
each centrifuge tube and then incubated at 37°C on an ThermoMixer R (Eppendorf, 
Hauppauge, NY) for 1 hour.  While the 37°C incubation is taking place, two Kanamycin 
LB agar plates (Teknova, Hollister, CA) are pre-warmed in the 37°C plate incubator.  
The entire contents of each culture are then transferred to 2 agar plates and spread until 
absorbed into the agar.  The plates were incubated upside-down at 37°C overnight. 
2.4 Culture and Protein Induction 
Transformed cells containing the  inducible vector were scraped off using a single 
edge industrial razor blade (VWR, West Chester, PA) and transferred into a 50 mL 
Polypropylene Conical Tube (Becton Dickinson Labware, Franklin Lakes, NJ).  The 50 
mL tube was then filled with 33 mL of Terrific Broth, vigorously vortexed, and incubated 
in a 37°C water bath for 10 minutes. 
A 4 mL aliquot of the culture was transferred into 8, 2800 mL Erlenmeyer flasks 
containing 1 liter of terrific broth with 50µg/mL Kanamycin.  The flasks were incubated 
at 37°C and shaken at 260 rpm.   
Cultures were induced with 0.1 mM isopropyl-B-D-Thiogalactopyranoside (EMD 
Chemicals, Gibbstown, NJ) when the optical density at 595nm reached approximately  
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0.60 to 1.00 measured with a spectrophotometer (Fisher Scientific, Hampton, NH).  
Once isopropyl-B-D-thiogalactopyranoside was added, the 8 liter cultures were incubated 
at 18°C for 4 hours. 
2.5 Protein Extraction and Purification 
Cultures were transferred from the 2800 mL Erlenmeyer flasks into 1 liter spin 
bottles designed for the RC-3B Refrigerated centrifuge with H6000 rotor and buckets 
(Block Scientific, Bohemia, NY).  The cultures were centrifuged for 10 minutes at 3000 
rpm. Media was decanted and the remaining pellets were scraped off and evenly 
distributed into 4, 50 mL polypropylene conical tubes.  Sonication buffer composed of 
300 mM Potassium chloride, 50 mM Trizma Base pH 8, 20 mM Imidazole, and 10% 
glyercol was added to the polypropylene conical tubes until a total volume of 
approximately 45 mL was reached and then the contents were vigorously vortexed and 
placed on ice.  The addition of 0.5 mM phenylmethylsulfonyl fluoride and 2 mM 
benzamidine protease inhibitors were required to protect our target protein from any 
detrimental protease activity.   
From this point on, the cultures were constantly on ice.  Cultures were lysed using 
a probe Sonicator 3000 (Misonix Inc, Farmingdale, NY) at maximum power for a burst 
of 5 seconds and subsequent cooldown for 5 seconds for total of 1 minute of sonication (2 
minutes total time). 
The cell lysates were evenly transferred into 26.3 mL polycarbonate centrifuge 
tubes (Beckman Instruments Inc. Palo Alto, CA) and placed in a Type Ti-70 Rotor 
constructed for the Optima L-80 XP Ultracentrifuge (Beckman Coulter, Brea, CA).  The 
lysates were centrifuged at 45,000 rpm for approximately an hour. 
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The supernatant was decanted.  Care was taken not to decant the loose membrane 
near the pellet. The remaining pellet and membrane were transferred to 50 mL 
polycarbonate conical tubes.  LDAO sonication buffer containing 300 mM Potassium 
chloride, 50 mM Trizma Base (Sigma-Aldrich, Saint Louis, MO) pH 8, 20 mM 
Imidazole, 10% glyercol and 20 mM N-N-dimethyldodecylamine-N-oxide (Affymetrix, 
Santa Clara, CA) was added to each tube until a total volume of 45 mL was reached.  
Pellets were solubilized by sonication in 5 second bursts with subsequent 5 second 
cooldown for a total of 1 minute of total sonication (2 minutes total time).  The 
solubilized pellets were transferred into the same 26.3 mL polycarbonate centrifuge 
tubes, and placed in the Type Ti-70 Rotor.  Solubilized pellets were centrifuged for 
45,000 rpm for 30 minutes. 
The supernatant containing the detergent solubilized membrane was equally 
decanted into 4, 50 mL conical tubes and 1 mL of His-Select Nickel Affinity Gel (Sigma-
Aldrich, Saint Louis, MO) was added to each of the 4 tubes and placed on a plate shaker 
at very low speeds for 30 minutes at 4°C. 
All tube contents were passed through 1 polypropylene chromatography column, 
allowing the excess buffer to pass and the nickel beads containing bound protein to 
remain.  Nickel beads were washed with 10 mL of LDAO Sonication Buffer [300 mM 
Potassium chloride, 50 mM Trizma Base pH 8, 20 mM Imidazole, 10% glyercol and 20 
mM N-N-dimethyldodecylamine-N-oxide] three times.  On the 2nd wash, 10 mL of 
Sonication Buffer containing one of 6 detergents in the screen (300 mM Potassium 
chloride, 50 mM Trizma Base pH 8, 20 mM Imidazole, 10% glyercol and 20 mM of 
detergent from screen (Affymetrix, Santa Clara, CA) was transitioned when 2 mL of 
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LDAO wash buffer remained in the column.  This was followed by 3 more 10 mL 
detergent screen buffer washes. 
Elution of the protein was conducted using 9 mL of elution buffer [300 mM 
Potassium chloride, 50 mM Trizma Base pH 8, 20 mM Imidazole, 10% glyercol and 20 
mM of detergent in screening, 880 mM Imidazole].  The entire elution buffer was added 
to the column and then collected.  1 mM tris(2-carboxyethyl)phosphine hydrochloride 
was added to the elution to prevent oxidative damage (Sigma-Aldrich, Saint Louis, MO). 
2.6 Size-Exclusion Chromatography and Multi-Angle Light Scattering Analysis 
The gel column, Superdex 200 prep grade (GE Healthcare, Piscataway, NJ) was 
equilibrated with reaction buffer (300 mM Potassium chloride, Trizma Base pH 8, 1 mM 
tris(2-carboxyethyl)phosphine hydrochloride, and 3 mM of detergent in screening). 
The 9 mL eluate from the extraction purification protocol was concentrated down 
to 2 mL using an Amicon Ultra-15 Centrifugal Filter Devices (Millipore, Billerica, MA).   
Protein preparation was loaded into the reaction buffer equilibrated Superdex 200 prep 
grade column and eluted at a rate of 1 mL/minute and fractions were collected in 2 mL 
intervals with a simultaneous MALS analysis using the minDAWN™ TREOS scanning 
detector (Wyatt Technology, Santa Barbara, CA). 
Two fractions, or 4 mL, at the sharpest absorbance peak were collected and 20 µL 
was used to determine protein concentration using  Protein Assay Dye (Bio-Rad, 
Hercules, CA) and 595 nm absorbance was measured with a spectrophotometer (Fisher 
Scientific, Hampton, NH) to calculate protein concentration by the Bradford method 
(Bradford, 1976). 
Protein in milligrams = absorbance at 595nm x 30/volume of protein in microliters x milliliters taken from fractions 
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2.8 Protein Dialysis 
Protein fractions were collected and concentrated in an Amicon Ultra-15 
Centrifugal Filter Device to 5 to 10 mgs/mL.  The protein sample was then transferred 
into a pre-rinsed dialysis membrane with a molecular weight cut off of 50,000 (Spectrum 
Labs, Greensboro, NC) to allow excess detergent micelles to diffuse out.  The membrane 
containing protein was dialyzed in 500 mL of dialysis buffer [10 mM Trizma Base pH 8, 
1 mM tris(2-carboxyethyl)phosphine hydrochloride, 3 mM N,N-
Dimethyllauramidopropylamine N-oxide] at 4°C overnight. 
2.9 Protein Crystal Screening and Optimization 
Initial crystal condition screening was performed using the JCSG+ Suite (Qiagen, 
Valencia, CA) using the hanging drop method of vapor diffusion.  The hanging drop 
diffusion method involves a silicone cover slide containing 2 µL of the protein sample 
mixed with 2 µL of a testing condition suspended over the “mother liquor” or 1 mL of the 
testing condition.  Through vapor equilibration of the unsaturated droplet and the mother 
liquor reservoir, the protein solution transitions to super saturation with the ultimate goal 
of producing protein crystals. 
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Figure 9: A.  Hanging drop method for protein crystal production.  B.  Solubility versus 
protein.  1.  Initial protein concentration in the hanging drop is in an unsaturated, soluble 
state.  2.  Through vapor-diffusion, solubility of the protein sample decreases allowing 
the hanging drop to transition into the labile region where stable nuclei spontaneously 
form and gro.  3.  After equilibration, the hanging drop may go into the metastable region 
where stable nuclei continue to grow but do not initiate (Adapted from Leunissen, 2001).   
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2.10 SDS-Page Analysis 
SDS-PAGE gels were custom made.  The 5 mL resolving gel was composed of 
10% acrylamide (EMD Chemicals, Gibbstown, NJ), 1.3 mL of 1.5M Trizma Base pH 
8.8, 10% Sodium dodecyl sulfate (Sigma-Aldrich, Saint Louis, MO), 10% Ammonium 
persulfate (Sigma-Aldrich, Saint Louis, MO) . Polymerization was induced by 1 µL of 2, 
3-dimethyl-2-butene (Sigma-Aldrich, Saint Louis, MO). 
The 2 mL stacking gel was composed of 5% acrylamide (EMD Chemicals, 
Gibbstown, NJ), 1.5 mL of  1.5M Trizma Base pH 6.8, 10% Sodium dodecyl sulfate 
(Sigma-Aldrich, Saint Louis, MO), 10% Ammonium persulfate (Sigma-Aldrich, Saint 
Louis, MO). Polymerization was induced by 1 µL of 2, 3-dimethyl-2-butene (Sigma-
Aldrich, Saint Louis, MO).  Protein was visualized using Coomassie blue staining. 
2.11 X-ray Diffraction Analysis 
Successful protein crystals were sent to Stanford Synchrotron Radiation 
Lightsource for x-ray analysis. 
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CHAPTER 3 
ANALYSIS AND CRYSTALLIZATION OF A BAX MULTIMER 
3.1 MisticBcl-2 Family Members Expression Behavior and  
Protein Expression Requires a Long Linker 
An array of Bcl-2 family constructs was expressed to test their ability to cooperate 
with a Mistic leader.  Criteria for success were graded by the intensity and homogeneity 
of the gel band, qualitatively characterized by SDS-PAGE. 
The preliminary expression results show that Bax with a long linker was a 
successful candidate for further study.  The significance of Bax in MOMP as well as its 
uncharacterized oligomeric state prompted us to focus our crystallization studies solely 
on Bax. 
Optimization of the linker length is vital in the expression of Bax signifying that 
conformation in the cell membrane is essential.  The target protein being trailed by Mistic 
requires correct positioning in relation to the membrane in order to properly fold.  In 
theory, if the construct lacks a linker or the linker is too short the Bax protein may be in 
close proximity to the membrane but may never embed.  On the other hand, a linker 
excessive in length is prone to proteolytic degradation where Bax may be cleaved before 
ever reaching the membrane. 
We facilitated the use of linker sequences between Mistic protein and the target 
Bax protein to obtain this membrane bound complex.  Linker constructs (small, medium, 
and large) were constructed and expressed with LDAO as the stabilizing detergent which 
is further detailed in section 3.2 “LDAO is Optimal for Membrane Extraction”.  The 
relative yields were qualitatively measured using SDS-PAGE 
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Figure 10:  MisticBcl-2 family expression library with differing linker lengths.  L=large 
linker, M=Medium linker, S= small linker TM= transmembrane helix.   - = no thrombin + 
= thrombin cut 
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Standard bacterial protein expression protocols were ineffective at 
producing workable quantities of Bax (<1 mg per 8 liter preparation).  Optimization of 
the protein preparation revealed significantly higher yields when membrane extraction 
and protein elution occur 4 hours after IPTG induction versus the standard overnight time 
period.  It is speculated that increasing aggregation of Bax at the bacterial membrane is 
toxic, leading to lower protein yields at time points exceeding 4 hours.  
 BaxMistic with a long linker (MisticBaxL) is the most efficient construct for 
expression.    Higher average yields of MisticBaxL (2.5 mgs to 4 mgs) was obtained with 
by sending the sequence for synthesis (DNA 2.0) that are optimized for bacterial 
expression.  The decision to stop utilizing thrombin to remove Mistic was made due to 
the incomplete or partial cutting due an unforeseen inhibition of thrombin when utilizing 
the detergent LAPAO.   Also, the C-terminus Strep-Tag II was not removed.  Constructs 
with a stop codon immediately after the Bax sequence interestingly destabilized Bax 
significantly. 
 
Figure 11: The linker length may affect protein expression.  1.  A linker too short may 
cause the target protein to preclude the cellular membrane. 2.  A linker too long is prone 
to proteolytic degradation.  3.  The use of a transmembrane helix may be necessary for 
correct orientation of the trailing protein to embed into the membrane. 
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A  B C  
Figure 12:  SDS PAGE of MisticBax Constructs.  A.  Original MisticBaxL B.  
Synthesized MisticBaxL C.  Synthesized MisticBaxL without Strep-Tag II  
3.2 LDAO is Optimal for Membrane Extraction 
Six detergents were tested to optimize expression yield and Bax complex stability. 
Protein samples were prepared as described in the methods section and the size exclusion 
Superdex 200PG column was equilibrated with the reaction buffer containing the same 
detergent.  Protein yield and stability was best attained when LDAO was initially used for 
membrane extraction and then the detergent was switched to LAPAO starting at the 2nd 
Ni+ column wash.  In an interesting note, what appears to be a higher-order form of Bax 
actually is an aggregation of nucleic acids.  This DNA peak can be maximized when the 
entire protein preparation is executed at 4°C with or without the attachment of Mistic.  
The cause of the nucleic acid contamination is unknown.  
 
 
 
35 kDa 
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Figure 13:  A.  LDAO extraction produces homogenous Bax.  A sharp oligomeric Bax 
peak is obtained in SEC analysis when membrane extraction is conducted with LDAO as 
the detergent and LAPAO as the solubilizing detergent. B.  DNA contamination.  The 
peak eluting before oligomeric Bax is a large aggregation of nucleic acids as 
demonstrated by DNA gel electrophoresis.     
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  ME: LDAO SD: Cymal-5     ME: LDAO SD: DDM      ME: LDAO SD: DM 
 
   ME:  LDAO SD: LDAO     ME: LDAO SD: UDM       ME:  LDAO SD: No Detergent 
 
ME: LAPAO SD: LAPAO 
Figure 14:  Detergents affect stability of protein sample.  ME= Detergent used during 
membrane extraction SD= Detergent used to solubilize protein.   X-axis = elution 
volume, Y-axis =UV absorbance (mAU). 
 42 
 
3.3 Bax not affected by Octahistidine-tag or Mistic 
 The decision to stop using thrombin to cleave the octahistidine tag and Mistic 
with linker was made due to the difficulty in cleaving the thrombin site.  Even at high 
concentration of thrombin (100 units), cleavage was incomplete.  SEC analysis shows 
that even with octahistidine tag and Mistic with linker still attached, Bax remained in 
oligomeric conformation. 
 
Figure 15: Bax oligomerization not affected by octahistidine tag or Mistic with linker.  
Black = MisticBax.  Red = Bax 
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3.4 Bax Oligomers Form Trimers 
 A SEC-MALS measurement was taken under a Bax preparation with DDM as the 
solubilizing detergent.  As shown in figure 14, the over-estimation of SEC to the 
molecular weight of protein/detergent complex run is apparent with the molecular mass 
reading at ~170 kDa.  In contrast, the multi-angle light scattering measurement of protein 
concentration shows that the protein/detergent complex is composed of almost equal 
parts protein and detergent at 75 kDa for a total of 150 kDa.  With Bax monomer being a 
~23 kDa protein, the molecular weight of this complex allows for three Bax monomers. 
 
 
Figure 16:  SEC-MALS measurement showing trimeric Bax. 
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3.5 LAPAO is the Optimal Detergent for Crystal Trials and  
Produces X-ray diffracting Crystals 
Crystal trials commenced using LDAO as membrane solubilizers were 
unsuccessful.  None of the 96 crystal trials in the JCSG+ suite produced any potential hits 
despite the relatively high yield and stable protein conformation.  This prompted us to 
remain using LDAO for membrane extraction while screening for another detergent 
capable of maintaining Bax in a trimeric conformation while promoting crystal growth. 
The first potential candidate for Bax solubilization was UDM.  Bax solubilized in 
UDM met the criteria for trimer stabilization in accordance to SEC and under hanging 
drop well conditions of 0.2M Magnesium chloride, 0.1M HEPES pH 7.5, and 30% v/v 
PEG 400 produced large crystals (approximately 20 x 15 x 10 uM). 
Unfortunately, physical handling of the crystal proved extremely difficult and can 
be described as touching an “ordered gel”.  Pursuit of a UDM-Bax crystal was finally 
halted when the protein crystal did not diffract X-rays.  
We were prompted to change protein detergents due to repeated formations of the 
“ordered gel” morphology.  The change to LAPAO as a protein solubilizer produced tiny 
“needles” in multiple +JCSG Suite conditions.  Subsequently, these conditions were 
pursued and optimized. 
One condition under 0.20M Potassium formate and 20% PEG3350 at 25°C 
produced sharp rod crystals (5 x 15 x 5 uM).  Use of the same protein preparation under 
an optimizing trial produced reproducible crystals.  The high percentage PEG3350 served 
as a cryoprotectant and the crystals were shipped to Stanford Synchrotron Radiation 
Lightsource for x-ray diffraction analysis. 
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Figure 17:  Bax crystals produced with UDM.  Condition:  0.1M HEPES pH 7.5, 30%v/v 
PEG 400, 0.2M Magnesium chloride at 25°C. 
 
 
 46 
 
 Unfortunately, conditions were unique to this protein preparation because crystals 
independent of this preparation could not be obtained.  After numerous attempts, we were 
forced to rescreen using the JCSG+ suite.  Luckily, more screening hits appeared when 
trials were incubated at 4°C.  We have recently obtained needle-like crystals in 20% 
Glycerol, 30% PEG 1000, and 0.30M Yttrium (II) chloride and are currently optimizing 
crystallization conditions. 
A B  
Figure 18:  A.  MisticBax rod crystals with LAPAO.  Condition: 0.20M Potassium 
formate and 20% PEG3350. B.  X-ray diffraction pattern. 
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Figure 19: MisticBax needle crystals.  Condition:  20% Glycerol, 30% PEG 1000, and 
0.30M Yttrium (II) chloride. 
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CHAPTER 4 
SUMMARY, CONCLUSIONS, AND RECOMMENDATIONS 
A recent study using a fluorescent Bax mutant lacking  α9 for fluorescence 
correlation spectroscopy and fluorescent-intensity distribution analysis has shown that 
soluble monomeric Bax remains monomeric even after integrating into the detergent 
micelles (Ivashyna et al., 2009).  In our research with full-length Bax, molecular weight 
contribution of detergent is approximately equal to protein contribution according to 
MALS.  This is in direct contradiction to those previous findings of monomeric Bax 
embedded within a large detergent micelle.  Our studies cannot support the formation of 
activated monomeric Bax embedded in a large detergent micelles and concretely 
reinforces the importance of α9 and in turn, full-length Bax when studying homo-
oligomerization of Bax proteins. 
The details of the multistep process of Bax activation leading to pore formation 
are highly disputed, but we are slowly chipping away at the details.  Until recently, how 
Bax activation, suppression, and oligomerization occurred with only one known protein 
assembly surface caused substantial confusion of the regulation mechanism of Bax. Some 
clarity was obtained after the discovery of a novel interaction site opposite of the BH3 
hydrophobic domain, capable of binding a stabilized α-helix of Bcl-2 (SAHB) domains of 
the BH3-only protein Bim.  This study showed that conformational change induced from 
an interaction site opposite of the BH3 hydrophobic domain was capable of dislodging 
the α9 helix and potentially allowing the oligomerization of other Bax proteins 
(Gavathiotis et al., 2008).  The study also suggests there must be at least one more  
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unidentified surface in addition to the BH3-hydrophobic domain and novel SAHB site on 
Bax that mediate homo-oligomerization.  What is glaringly missing from the current 
models of high order Bax oligomerization is the presence of a cell membrane in the 
conformational change of Bax oligomers.  Our formation of a “never before seen” Bax 
trimer is evidence that membrane induced conformational change exists.   
In the presence of a membrane, detergents produced stable trimers, even when 
using some of the same detergents, such as LDAO and DDM, used in “membraneless” 
dimer studies. The importance of a membrane is further reinforced with studies able to 
form functional Bax pore structures in a liposome (Bleicken et al., 2009). It is therefore 
essential that further research of the pore forming Bax oligomers require a cell membrane 
for higher-order activation.  
 
 
Figure 20: Mechanism of Bax dimerization.  A BH3-only molecule binds to a novel site 
on the opposite side to the BH3 hydrophobic domain of Bax.  This dislodges α9, 
exposing the BH3 hydrophobic surface for homo-oligomerization (Adapted from 
Gavathiotis et al., 2008) 
Presuming the end product of Bax oligomer is a ring structure that allows the 
diffusion of cytochrome c, we theorize the dimer Bax model must be a transient structure 
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seen only in vivo during cytosol to mitochondrial membrane translocation.  We propose 
that once Bax reaches the membrane, another membrane-induced conformational change 
occurs allowing for additional Bax monomers to attach from 2 sides of each Bax 
molecule.  The initial state leads to a pre-pore trimer but binding of BH3 molecules to the 
complex allows for the addition of Bax subunits to the oligomeric complex.  This 
continues until a pore large enough for cytochrome c to diffuse through is formed leading 
to the cell death. The proposed mechanism is outlined in Figure 21. 
 
Mitochondrial Membrane
Cytosol
Monomeric inactive Bax conformation is changed by a BH3-only 
protein attaching to its back, exposing a hydrophobic domain in the 
front
While translocating to the mitochondrial membrane, dimerization
can occur.  In absence of a membrane, dimerization persists
Activated Bax translocates to the mitochondrial 
membrane.  Attachment to the  membrane causes 
another conformational change, exposing a second 
unseen active site and allowing the initial 
oligomerization stages
A BH3-only protein 
allows another monomer 
of Bax to squeeze to the 
trimer complex
Addition of subunits until 
formation of pore
 
Figure 21:  Proposed Bax oligomerization mechanism 
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In pursuit of x-ray diffracting protein crystals of Bax, we have overcome many 
pitfalls that plague the field of protein crystallography.  Membrane protein production is 
an early hurdle for many IM protein studies yet, the effectiveness of Mistic allowed for 
the production of the first x-ray diffracting protein crystal of an oligomeric Bax.  We 
have tested over 8,700 total crystallization condition trials.  Approximately 40% were 
screening trials with the remaining trials optimizing “hits” of the conducted screen.  
Although 95% of the trials conducted were in room temperature conditions, recently, cold 
room trials appear to be the most promising as the small crystals are highly reproducible.  
With typical protein crystallography projects ranging in the tens of thousands of trials to 
solve a structure, we remain more than optimistic that we will obtain multiple protein 
crystals of Bax for a complete high resolution 3D protein structures.  
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APPENDIX 
  My experiences with success in developing protein purification protocols and 
executing effective protein crystallography trials has expanded to other proteins other 
then Bax described in this thesis.  I have assisted in the production of two protein 
structures of the human protein uridine phosphorylase 2 (UPP2) in active conformation 
with bound 5-benzylacyclouridine and also the inactive conformation of UPP2 with 
bound 5-benzylacyclouridine.  Both structures have been published in the RCSB Protein 
Data Bank (PDB IDs 3P0E & 3P0F) as well as a pending publication in The Journal of 
Biological Chemistry entitled “A Novel Structural Mechanism for Redox Regulation of 
Uridine Phosphorylase 2 Activity”. 
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